Trial Condition(s):

Endometriosis

Visanne Post-approval Observational Study (VIPOS) (VIPOS)

Bayer Identifier:

15214

ClinicalTrials.gov Identifier:

NCT01266421

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The study assesses safety aspects of Dienogest (DNG) 2mg/day (Visanne) used as endometriosis therapy and of other hormonal treatments for endometriosis.

Inclusion Criteria
- Women using a newly prescribed regimen for endometriosis (first-time users or switchers)
- Women who are willing to participate in this long-term follow-up study
Exclusion Criteria
- Women who are not cooperative/available for follow-up
- Women with a language barrier

Trial Summary

Enrollment Goal
27840
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Visanne (Dienogest, BAY86-5258)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, Germany

Status
Completed
 
Locations

Investigative Site

Many locations, Poland

Status
Completed
 
Locations

Investigative Site

Many locations, Hungary

Status
Completed
 
Locations

Investigative Site

Many locations, Switzerland

Status
Completed
 
Locations

Investigative Site

Many locations, Russia

Status
Completed
 
Locations

Investigative Site

Many locations, Ukraine

Status
Completed
 

Trial Design